Was Rova-T Worth The High Price To AbbVie?

The big pharma presented early-stage data for its antibody drug conjugate at the American Society of Clinical Oncology (ASCO) in Chicago that showed promise for the drug in a small subset of patients with small cell lung cancer, but had disappointing results for the overall population.